Introduction: Falls and subsequent fractures represent a major public health concern among older adults. While fall prevention interventions have demonstrated efficacy in reducing falls, their impact on fracture outcomes remains unclear. Methods: We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. We searched multiple databases up to 7 June 2025 for studies investigating fall prevention interventions and fracture outcomes in community-dwelling older adults. A primary outcome was hip fractures; secondary outcomes included any fractures, falls, and serious fall injuries. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated, using random-effects meta-analysis where appropriate. Results: Seventeen studies were included, spanning over 25,000 participants. Interventions included exercise programs, multifactorial approaches, medication optimization, and vitamin D supplementation. For hip fractures, only two randomized controlled trials (RCTs) reported extractable outcome data (12,489 participants; 132 events); both showed non-significant reductions favoring intervention (RR 0.80–0.87), precluding pooled meta-analysis. For any fractures, five studies (18,519 participants; 1343 events) demonstrated no significant effect (RR 0.91, 95% CI 0.72–1.14; p-value = 0.40) with significant heterogeneity (I² = 65%). Fall prevention interventions significantly reduced falls across 14 studies. GRADE assessment indicated very low certainty for both hip fractures and any fractures due to limited studies, inconsistency, and imprecision. Conclusions: Current evidence suggests fall prevention interventions may reduce hip fractures but do not significantly prevent fractures overall. Despite consistent fall reduction, the translation to fracture prevention remains uncertain, highlighting the need for integrated interventions targeting both fall risk and bone health.

Background: Visceral embolic events (VEE), including mesenteric, splenic, and renal infarctions, represent understudied complications of atrial fibrillation (AF) often subsumed within broader systemic embolic event categories. The 2024 European Society of Cardiology guidelines introduced the CHA₂DS₂-VA score, removing female sex as a risk modifier, with potential implications for non-cerebral embolic risk stratification. We systematically synthesized evidence on VEE incidence, mortality, and risk predictors in AF patients. Methods: We searched PubMed, Embase, Scopus, and Web of Science through September 2024 for studies reporting VEE in AF populations. Study quality was assessed using the Newcastle–Ottawa Scale (NOS). Due to substantial heterogeneity when pooling all prevalence studies (I² = 99.6%), we performed event-definition-based subgroup analyses. Random-effects meta-analyses were conducted using DerSimonian–Laird methods with 95% prediction intervals. Sensitivity analyses excluded studies with NOS scores < 7 to assess robustness. Results: We identified 12 studies including 329,128 patients. Quality assessment revealed a mean NOS score of 6.7 ± 1.6 (range: 4–9), with 75% of studies achieving good-to-excellent ratings. For non-AMI visceral embolic events (splenic, renal, mesenteric infarctions), subgroup meta-analysis of three studies (n = 548) yielded a pooled prevalence of 1.6% (95% CI: 0.0–3.2%, I² = 45.4%, p = 0.160), representing a 54.2 percentage point reduction in heterogeneity compared to pooling all event types. Sensitivity analysis excluding moderate-quality studies confirmed robust findings (pooled prevalence 2.7%, 95% CI: 0.0–6.8%, I² = 70.3%). Incidence rates ranged from 0.36 to 3.48 per 1000 person-years across three cohort studies (I² = 99.4%), reflecting temporal and geographic variation. Mortality varied substantially by patient population: 64.0% in-hospital mortality among elderly patients with concurrent acute myocardial infarction (AMI) versus 17.4% in younger cohorts with isolated non-AMI VEE. Potential predictors included left atrial enlargement (OR range: 2.1–4.3), elevated D-dimer (OR: 3.2), and higher CHA₂DS₂-VASc scores (OR: 1.3 per point increase), though validation in independent cohorts is lacking. Conclusions: Visceral embolic events occur in approximately 1–6% of AF patients, with mean prevalence of 1.6% for non-AMI events based on moderate-heterogeneity meta-analysis. Event-definition-based subgrouping successfully reduced heterogeneity from 99.6% to 45.4%, providing the first reliable pooled estimate for this outcome. Mortality ranges widely (17–64%) depending on concurrent AMI and patient age. Potential predictors including left atrial enlargement and elevated D-dimer require prospective validation before clinical implementation. These findings suggest VEE may warrant enhanced clinical awareness and individualized risk assessment strategies in AF management, pending validation in prospective studies.